Author: Web Desk

NORTHAMPTON, MA / ACCESSWIRE / February 1, 2024 / Atlantic City Electric:

Saundra Wilson, Senior Fleet Manager, received Exelon’s Powering Communities Employee Volunteer Award, the organization’s highest achievement for volunteerism and community involvement, for her work with Loving Our Cities. Alongside Saundra’s recognition, Loving Our Cities also received a $5,000 grant to invest in its community support programs.

For nine years, Saundra has worked with Loving Our Cities, a New Jersey-based nonprofit that aims to improve the quality of life within its communities. Saundra volunteers each Saturday at the Hope Winslow Mobile Food Pantry, helping distribute food to community members and use the skills she gained as a trainer at Atlantic City Electric to help register and organize the members.

Recently, Saundra celebrated her 38th anniversary of working at Atlantic City Electric. She credits the business with her motivation for volunteering, "The company has been great with servicing me, providing me opportunities to work, to learn, to get educated, and I feel like I need to give back to the community and the company promotes that."

In 2022, Atlantic City Electric employees volunteered more than 10,000 hours – which is more than 1,250 workdays – to support 125 different events throughout South Jersey. This volunteerism is on top of the approximately $1.2 million Atlantic City Electric contributed to local nonprofits.

Atlantic City Electric is a unit of Exelon (Nasdaq: EXC), a Fortune 250 company and the nation’s largest utility company, serving more than 10 million customers. Atlantic City Electric provides clean, safe, reliable and affordable energy service to approximately 565,000 customers in southern New Jersey.

To learn more about Atlantic City Electric, visit The Source, Atlantic City Electric’s online newsroom. Find additional information by visiting atlanticcityelectric.com, on Facebook at facebook.com/AtlanticCityElectric, and on Twitter at twitter.com/AcEleCconnect. Atlantic City Electric’s mobile app is available at atlanticcityelectric.com/MobileApp.

View original content here.

View additional multimedia and more ESG storytelling from Atlantic City Electric on 3blmedia.com.

Contact Info:

Spokesperson: Atlantic City Electric
Website: https://www.3blmedia.com/profiles/atlantic-city-electric
Email: info@3blmedia.com

SOURCE: Atlantic City Electric

View the original press release on accesswire.com

Correction: Extended clarification.

HALIFAX, NS / ACCESSWIRE / February 1, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) is pleased to provide an update on the ongoing review process by Health Canada. The Company made the submission and since then has been working with the regulator on the additional clarifications and at the same time has been working towards extending its intended use highlighting the increasing need in maternity screening.

MedMira is committed to provide the fastest and most accurate solution to the increasing infection rates for infectious and congenital syphilis. Whereas the infection rates over the past 10 years increased by 73% among males, the rate among females increased by 773%. As a result, congenital syphilis (syphilis transmitted during pregnancy to babies) led to a rise in severe and life-threatening illnesses with up to 40% of babies being stillborn.

The Company’s syphilis component showcased an overall performance of a PPA of 86.0% (95% CI 82.7-88.8%) and an NPA of 99.5% (98.8-99.8%). Notably, when the RPR titre was > 1:8 dilutions-indicative of an infectious case-the performance significantly improved to a PPA of 98.3% (95.7-99.3%) and an NPA of 99.5% (98.8-99.8%). This is particularly promising as it aligns with the marker for newly diagnosed infectious syphilis cases the study.

Furthermore, in a subset analysis involving specimens from women at various pregnancy stages, the MedMira’s test exhibited high quality results. Specifically, the test accurately identified all previously syphilis-infected cases, demonstrated reliability in confirming negatives, and presented potential for maternity screening. In order to demonstrate this, the Company expanded its overall data pool with additional specimens including those from various pregnancy stages among negative and positive syphilis cases. This is the final comprehensive data set to be submitted by the end of February 2024 for the additional claims approval.

"We are excited about the data achieved which underline the high quality of our products. It is my firm believe that the data will be a positive proof our capability and quality, not only for regulators but also for our future customers." said Hermes Chan, CEO of MedMira. "We remain committed to advancing healthcare solutions in Canada and we look forward to the positive impact our tests can have on public health."

About MedMira

MedMira is a leading developer and manufacturer of Rapid Vertical Flow^® diagnostics. The Company’s tests provide hospitals, labs, clinics and individuals with instant disease diagnosis, such as HIV, Syphilis, Hepatitis, and SARS-CoV-2, in just three easy steps. The Company’s tests are sold globally under the REVEAL^®, REVEALCOVID-19^®, Multiplo^® and Miriad^® brands. Based on its patented Rapid Vertical Flow^® Technology, MedMira’s rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira’s corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit medmira.com. Follow us on Twitter and LinkedIn.

This news release contains forward‐looking statements, which involve risk and uncertainties and reflect the Company’s current expectation regarding future events, including statements regarding possible regulatory approval, product launch, future growth, and new business opportunities. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

MedMira Contact

Markus Meile
Chief Financial Officer
MedMira Inc.
ir@medmira.com

SOURCE: MedMira Inc.

View the original press release on accesswire.com

Correction: Extended clarification.

HALIFAX, NS / ACCESSWIRE / February 1, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) is pleased to provide an update on the ongoing review process by Health Canada. The Company made the submission and since then has been working with the regulator on the additional clarifications and at the same time has been working towards extending its intended use highlighting the increasing need in maternity screening.

MedMira is committed to provide the fastest and most accurate solution to the increasing infection rates for infectious and congenital syphilis. Whereas the infection rates over the past 10 years increased by 73% among males, the rate among females increased by 773%. As a result, congenital syphilis (syphilis transmitted during pregnancy to babies) led to a rise in severe and life-threatening illnesses with up to 40% of babies being stillborn.

The Company’s syphilis component showcased an overall performance of a PPA of 86.0% (95% CI 82.7-88.8%) and an NPA of 99.5% (98.8-99.8%). Notably, when the RPR titre was > 1:8 dilutions-indicative of an infectious case-the performance significantly improved to a PPA of 98.3% (95.7-99.3%) and an NPA of 99.5% (98.8-99.8%). This is particularly promising as it aligns with the marker for newly diagnosed infectious syphilis cases the study.

Furthermore, in a subset analysis involving specimens from women at various pregnancy stages, the MedMira’s test exhibited high quality results. Specifically, the test accurately identified all previously syphilis-infected cases, demonstrated reliability in confirming negatives, and presented potential for maternity screening. In order to demonstrate this, the Company expanded its overall data pool with additional specimens including those from various pregnancy stages among negative and positive syphilis cases. This is the final comprehensive data set to be submitted by the end of February 2024 for the additional claims approval.

"We are excited about the data achieved which underline the high quality of our products. It is my firm believe that the data will be a positive proof our capability and quality, not only for regulators but also for our future customers." said Hermes Chan, CEO of MedMira. "We remain committed to advancing healthcare solutions in Canada and we look forward to the positive impact our tests can have on public health."

About MedMira

MedMira is a leading developer and manufacturer of Rapid Vertical Flow^® diagnostics. The Company’s tests provide hospitals, labs, clinics and individuals with instant disease diagnosis, such as HIV, Syphilis, Hepatitis, and SARS-CoV-2, in just three easy steps. The Company’s tests are sold globally under the REVEAL^®, REVEALCOVID-19^®, Multiplo^® and Miriad^® brands. Based on its patented Rapid Vertical Flow^® Technology, MedMira’s rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira’s corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit medmira.com. Follow us on Twitter and LinkedIn.

This news release contains forward‐looking statements, which involve risk and uncertainties and reflect the Company’s current expectation regarding future events, including statements regarding possible regulatory approval, product launch, future growth, and new business opportunities. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

MedMira Contact

Markus Meile
Chief Financial Officer
MedMira Inc.
ir@medmira.com

SOURCE: MedMira Inc.

View the original press release on accesswire.com

FAIRFIELD, NJ / ACCESSWIRE / February 1, 2024 / Jerash Holdings (US), Inc. (NASDAQ:JRSH) (the "Company" or "Jerash"), which manufactures and exports custom, ready-made, sportswear and outerwear for leading global brands, today announced it will release its financial results for fiscal 2024 third quarter ended December 31, 2023, before the market opens on Thursday, February 8, 2024. The Company will host an investor conference call the same day.

Call Date: Thursday, February 8, 2024

Time: 9:00 a.m. ET

Phone: 888-506-0062 (domestic); 973-528-0011 (international)

Conference ID: 964050

A live and archived webcast will be available online in the investor relations section of Jerash’s website at www.jerashholdings.com. For those who are not able to listen to the live broadcast, the call will be archived for approximately one year on the website.

About Jerash Holdings (US), Inc.

Jerash Holdings manufactures and exports custom, ready-made, sportswear and outerwear for leading global brands and retailers, including VF Corporation (which owns brands such as The North Face, Timberland, and Vans), New Balance, G-III (which licenses brands such as Calvin Klein, Tommy Hilfiger, DKNY, and Guess), American Eagle, and Skechers. Jerash’s existing production facilities comprise six factory units and four warehouses, and Jerash currently employs approximately 5,000 people. Additional information is available at www.jerashholdings.com.

# # #

Contact:

PondelWilkinson Inc.
Judy Lin or Roger Pondel
310-279-5980
jlin@pondel.com

SOURCE: Jerash Holdings (US), Inc.

View the original press release on accesswire.com

LAVAL, QC / ACCESSWIRE / February 1, 2024 / Bausch Health Companies Inc. (NYSE/TSX:BHC) will release fourth-quarter and full-year 2023 financial results on Thursday, Feb. 22, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.

Conference Call Details

Date:	Thursday, Feb. 22, 2024
Time:	8:00 a.m. U.S. EST
Webcast:	http://ir.bauschhealth.com/events-and-presentations

A replay of the conference call will be available on the investor relations website.

To participate in the live Q&A session, please register using this link to receive a PIN, which will be sent an hour before the conference call.

About Bausch Health

Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health outcomes. We develop, manufacture and market a range of products, primarily in gastroenterology, hepatology, neurology, dermatology, medical aesthetic devices, international pharmaceuticals, and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn.

Investor Contact:	Media Contact:
ir@bauschhealth.com	Kevin Wiggins
(877) 281-6642 (toll-free)	corporate.communications@bauschhealth.com
	(908) 541-3785

SOURCE: Bausch Health Companies Inc.

View the original press release on accesswire.com

Marking its First Anniversary, Spoutible Showcases Major Milestones in Creating a Safe, Inclusive Online Platform

NEW YORK, NY / ACCESSWIRE / February 1, 2024 / One year ago, Spoutible embarked on a mission to reshape the social media landscape as one of the few Black-owned social media platforms, focusing on diversity, inclusivity, and user safety. Today, Spoutible celebrates its first anniversary, reflecting on a year of significant achievements and community-driven success.

Founded with a vision to combat online harassment, hate speech, and misinformation, Spoutible has quickly become a haven for meaningful online interactions. With strict policies and transparent rules, the platform is a testament to safe and respectful online communication.

Spoutible’s first year has been marked by explosive organic growth, with impressive user engagement statistics, including millions of monthly visits and page views. This growth reflects the platform’s success in maintaining active and consistent user interactions.

Key to Spoutible’s appeal is its innovative features, such as a fully customizable timeline, auto-threading, AI-generated thread summaries, cross-platform posting to Bluesky and Mastodon, and interactive audio chat rooms called Pods, enhancing the user experience. These features, coupled with a high rating on app stores, underscore the platform’s commitment to user-centric design and innovative features.

Looking ahead, Spoutible is not resting on its laurels. The platform plans to introduce new features like an AI assistant to help users navigate the platform and interest-based connections to connect users based on shared interests, further enhancing user engagement and satisfaction.

"We are immensely proud of what we have achieved in just one year," says Christopher Bouzy, Founder & CEO. "Our success is a testament to the power of community support and our unwavering commitment to creating a safer online environment for all."

In addition to these milestones, Spoutible has recently achieved a significant financial accomplishment. The platform successfully raised nearly $600,000 through a Wefunder campaign for its seed round. This fundraising was notably backed by over 1,400 Spoutible community members, demonstrating Spoutible’s supporters’ strong belief and commitment to the platform’s vision and potential. This financial injection will be instrumental in supporting the continued development of innovative features and the platform’s expansion.

As Spoutible enters its second year, it embraces the promising opportunities of maintaining its distinctive position in the competitive social media landscape. The platform’s commitment to creating a safer and more inclusive online environment remains at the forefront of its mission. This next phase in Spoutible’s journey will be crucial as it seeks to balance growth and innovation with its foundational values of user safety, diversity, and inclusivity. The progress and adaptations of Spoutible in this dynamic social media environment will be a subject of interest for both industry observers and social media users alike.

Contact Information:

Phil Schnyder
COO
press@spoutible.com
888-958-1324

SOURCE: Spoutible Inc.

View the original press release on newswire.com.